Claims for Patent: 11,491,176

Summary for Patent: 11,491,176

Title:	Methods for treating or preventing ophthalmological conditions
Abstract:	The present invention relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering Antagonist A or another pharmaceutically acceptable salt thereof, optionally in combination with another treatment, to a subject in need thereof. The present invention also relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering an anti-C5 agent (e.g., ARC1905), optionally in combination with another treatment, to a subject in need thereof.
Inventor(s):	Samir Patel, Richard Everett, Douglas Brooks, Shane Xinxin Tian
Assignee:	Astellas US LLC
Application Number:	US17/676,811
Patent Claims:	1. A method of treating geographic atrophy (GA) in a human subject in need thereof, the method comprising administering to the eye of said subject from about 0.3 mg/eye to about 5 mg/eye of a pegylated aptamer; wherein the aptamer comprises the sequence (SEQ ID NO: 26) fCmGfCfCGfCmGmGfUfCfUfCmAmGmGfCGfCfUmGmAmGfUfCfUmG mAmGfUfUfUAfCfCfUmGfCmG--3T, wherein fC and fU=2′-fluoro nucleotides, mG and mA=2′-OMe nucleotides, all other nucleotides are 2′-OH, and 3T indicates an inverted deoxythymidine, or a salt thereof; wherein administration of the pegylated aptamer reduces growth of a lesion associated with geographic atrophy in the subject; and wherein the pegylated aptamer is administered to the subject biweekly, monthly, or quarterly; and wherein the pegylated aptamer is an anti-C5 agent. 2. The method according to claim 1, wherein the pegylated aptamer is provided as a pegylated moiety conjugated to the aptamer via a linker. 3. The method according to claim 2, wherein the pegylated moiety is conjugated to the 5′ end of the aptamer. 4. The method according to claim 2, wherein the pegylated moiety is a branched PEG. 5. The method according to claim 2, wherein the pegylated moiety has a molecular weight greater than about 10 kDA. 6. The method according to claim 2, wherein the pegylated moiety has a molecular weight of about 40 kDa. 7. The method according to claim 1, wherein the pegylated moiety has the following structure: 8. The method according to claim 1, wherein administration of the agent reduces a lesion associated with geographic atrophy in the subject. 9. The method according to claim 8, wherein the growth of the GA lesion in the subject in need thereof is reduced by at least 10% as compared to a subject who is not administered the anti-C5 agent. 10. The method according to claim 1, wherein the anti-C5 agent is administered monthly. 11. The method according to claim 10, wherein the anti-C5 agent is administered monthly for three injections, and the fourth and fifth injections are administered three or four months after the third injection. 12. The method according to claim 1, wherein the anti-C5 agent is administered bimonthly. 13. The method according to claim 1, wherein the anti-C5 agent is administered quarterly. 14. The method according to claim 1, wherein about 0.5 mg to about 2 mg/eye of a pegylated aptamer is administered to the subject. 15. The method according to claim 1, wherein about 1 mg/eye of a pegylated aptamer is administered to the subject. 16. The method according to claim 1, wherein the pegylated aptamer is provided as a granulate, suspension, emulsion, solution, gel, hydrogel, paste, ointment, cream, plaster, delivery device, injectable, implant, intraocular implant, spray, drop or aerosol. 17. The method according to claim 1, wherein administration is intravitreal or periocular. 18. The method according to claim 1, wherein administration is to the anterior or posterior chamber of the subject's eye. 19. The method according to claim 1, wherein the pegylated aptamer is provided as a controlled release formulation.